<DOC>
	<DOCNO>NCT00002084</DOCNO>
	<brief_summary>To determine safety efficacy oral valacyclovir hydrochloride ( 256U87 ) compare acyclovir treatment recurrent anogenital herpes HIV-infected patient CD4 count = &gt; 100 cells/mm3 .</brief_summary>
	<brief_title>A Comparative Trial Valacyclovir Hydrochloride ( 256U87 ) Acyclovir Suppression Anogenital Herpes Infections HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpesviridae Infections</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection CD4 count = &gt; 100 cells/mm3 . Documented culture anogenital herpes simplex virus ( HSV ) within last 5 year . History recurrent anogenital HSV infection , recurrence ( without culture ) within 1 year prior study . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malabsorption vomit would potentially limit retention absorption oral therapy . Concurrent Medication : Excluded : Systemic antiherpes medication . Interferon . Patients follow prior condition exclude : History hypersensitivity acyclovir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Acyclovir</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anus Diseases</keyword>
	<keyword>Herpes Genitalis</keyword>
</DOC>